• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Iridex, Peregrine enter agreement

Article

Iridex Corp. has entered into a global distribution and supply agreement with Peregrine Surgical Ltd. to become a worldwide distributor for Peregrine labeled products, and Peregrine Surgical will become part of the Iridex supply chain.

Mountain View, CA-Iridex Corp. has entered into a global distribution and supply agreement with Peregrine Surgical Ltd. Under the agreement, Iridex will become a worldwide distributor for Peregrine labeled products, and Peregrine Surgical will become part of the Iridex supply chain for the manufacture of certain Iridex products.

“Peregrine is an ideal partner to assist Iridex in not only broadening our channel offering and driving costs out of our supply chain, but we anticipate our partnership will also accelerate product development cycles for new disposable products,” said Will Moore, president and chief executive officer of Iridex.

The arrangement involves Iridex assuming management of Peregrine Surgical’s independent distribution channel in the United States. The integration should provide additional coverage and leverage for both company’s product lines, according to the company.

“Peregrine Surgical has invested in establishing high-quality and efficient manufacturing of surgical instruments,” stated Todd Richmond, president of Peregrine Surgical. “The global reach of Iridex will represent a mutually beneficial partnering for the brand names of both companies.”

For more articles in this issue of Ophthalmology Times eReport, click here.

Related Videos
Paul Badawi, co-founder and CEO of Sight Sciences, chats with Neda Shamie, MD, about what drives him
© 2024 MJH Life Sciences

All rights reserved.